Literature DB >> 17348845

Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues.

Pierfrancesco Tassone1, Pierosandro Tagliaferri, Maria Teresa Fulciniti, Maria Teresa Di Martino, Salvatore Venuta.   

Abstract

It is a current idea that carcinogenesis as well as tumor progression are dynamic processes, which involve inherited as well as somatic mutations and include a continuing adaptation to different microenvironmental conditions. There is, in fact, rising evidence that tumor cells are under a persistent stress and that autocrine as well as microenvironment-derived survival factors play a substantial role for the final outcome of the tumor development as well as for response to the anti-tumor therapy. We will review current achievements on the molecular biology of the microenvironment-derived survival signaling and therapeutical approaches, which are presently under clinical development. By the use of plasma cell disorders as an outstanding clinical model, we will discuss the development of novel in vivo preclinical models which recapitulate the human bone marrow milieu. Finally, we will discuss several topics which appear to be relevant for a successful clinical translation of preclinical research in this specific field.

Entities:  

Mesh:

Year:  2007        PMID: 17348845     DOI: 10.2174/138161207780162872

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

Review 1.  Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.

Authors:  P Tassone; P Neri; R Burger; M T Di Martino; E Leone; N Amodio; M Caraglia; P Tagliaferri
Journal:  Curr Cancer Drug Targets       Date:  2012-09       Impact factor: 3.428

2.  A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.

Authors:  T Calimeri; E Battista; F Conforti; P Neri; M T Di Martino; M Rossi; U Foresta; E Piro; F Ferrara; A Amorosi; N Bahlis; K C Anderson; N Munshi; P Tagliaferri; F Causa; P Tassone
Journal:  Leukemia       Date:  2011-01-14       Impact factor: 11.528

3.  The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.

Authors:  Monika Kusio-Kobialka; Paulina Podszywalow-Bartnicka; Philippos Peidis; Eliza Glodkowska-Mrowka; Kamila Wolanin; Grzegorz Leszak; Ilona Seferynska; Tomasz Stoklosa; Antonis E Koromilas; Katarzyna Piwocka
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

4.  In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.

Authors:  Maria Teresa Di Martino; Annamaria Gullà; Maria Eugenia Gallo Cantafio; Marta Lionetti; Emanuela Leone; Nicola Amodio; Pietro Hiram Guzzi; Umberto Foresta; Francesco Conforti; Mario Cannataro; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Oncotarget       Date:  2013-02

Review 5.  MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment.

Authors:  Lavinia Raimondi; Angela De Luca; Eugenio Morelli; Gianluca Giavaresi; Pierosandro Tagliaferri; Pierfrancesco Tassone; Nicola Amodio
Journal:  Biomed Res Int       Date:  2016-01-04       Impact factor: 3.411

6.  Oncogenic role of microRNA-20a in human multiple myeloma.

Authors:  Ting Wang; Wei Tao; Lei Zhang; Shengli Li
Journal:  Onco Targets Ther       Date:  2017-09-11       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.